Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 5/2011

01-10-2011 | SHORT REPORT

Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan

Authors: Moon Jin Kim, Gyeong-Won Lee, Jong Woo Seo, Hyun-Jung Kim, Sung-Nam Lim, Cheolwon Suh

Published in: Investigational New Drugs | Issue 5/2011

Login to get access

Summary

There is no previous report of fatal interstitial pneumonitis related to the administration of yttirum-90 ibritumomab tiuxetan. We report first case of fatal interstitial pneumonitis in a 35-year-old female patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan. A pathological evaluation through a surgical lung biopsy demonstrated a “interstitial pneumonitis” pattern. Although high-dose methylprednisolone was administered, she died due to acute respiratory distress syndrome, secondary to radioimmunotherapy-induced interstitial pneumonitis. In this report, we discuss the etiology, diagnosis, and management of radioimmunotherapy-induced interstitial pneumonitis.
Literature
1.
Marcus R (2005) Use of 90Y-ibritumomab tiuxetan in non-Hodgkin’s lymphoma. Semin Oncol 32:S36–S43PubMedCrossRef
2.
Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453–2463PubMedCrossRef
3.
Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S et al (2003) Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. J Nucl Med 44:465–474PubMed
4.
Macklis RM, Pohlman B (2006) Radioimmunotherapy for non-Hodgkin’s lymphoma: a review for radiation oncologists. Int J Radiat Oncol Biol Phys 66:833–841PubMedCrossRef
5.
Burton C, Kaczmarski R, Jan-Mohamed R (2003) Interstitial pneumonitis related to rituximab therapy. N Engl J Med 348:2690–2691PubMedCrossRef
6.
Macartney C, Burke E, Elborn S, Magee N, Noone P, Gleadhill I et al (2005) Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin’s lymphoma following R-CHOP and pegylated filgrastim. Leuk Lymphoma 46:1523–1526PubMedCrossRef
7.
Kim KM, Kim HC, Jeon KN, Kim HG, Kang JH, Hahm JR et al (2008) Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. Yonsei Med J 49:155–158PubMedCrossRef
8.
Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P (2009) The late adverse events of rituximab therapy—rare but there! Leuk Lymphoma 50:1083–1095PubMedCrossRef
9.
DeMonaco NA, McCarty KS Jr, Joyce J, Jacobs SA (2007) Focal radiation fibrosis after radioimmunotherapy for follicular non-Hodgkin lymphoma. Clin Lymphoma Myeloma 7:369–372PubMedCrossRef
10.
Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT et al (2008) Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 31:431–438PubMedCrossRef
11.
Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK (1997) Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 24:293–298PubMed
12.
Slauson DO, Hahn FF, Benjamin SA, Chiffelle TL, Jones RK (1976) Inflammatory sequences in acute pulmonary radiation injury. Am J Pathol 82:549–572PubMed
13.
Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS et al (1995) Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33:919–924PubMedCrossRef
14.
Peerzada MM, Spiro TP, Daw HA (2010) Pulmonary toxicities of biologics: a review. Anticancer Drugs 21:131–139PubMedCrossRef
15.
Demedts M, Costabel U (2002) ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J 19:794–796PubMedCrossRef
16.
Hubbard R, Venn A, Smith C, Cooper M, Johnston I, Britton J (1998) Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case—control study. Am J Respir Crit Care Med 157:743–747PubMed
17.
Scott J, Johnston I, Britton J (1990) What causes cryptogenic fibrosing alveolitis? A case—control study of environmental exposure to dust. Br Med J 301:1015–1017CrossRef
18.
Hubbard R, Lewis S, Richards K, Johnston I, Britton J (1996) Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 347:284–289PubMedCrossRef
19.
Camus P, Kudoh S, Ebina M (2004) Interstitial lung disease associated with drug therapy. Br J Cancer 91:S18–S23PubMedCrossRef
20.
Merad M, Le Cesne A, Baldeyrou P, Mesurolle B, Le Chevalier T (1997) Docetaxel and interstitial pulmonary injury. Ann Oncol 8:191–194PubMedCrossRef
Metadata
Title
Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan
Authors
Moon Jin Kim
Gyeong-Won Lee
Jong Woo Seo
Hyun-Jung Kim
Sung-Nam Lim
Cheolwon Suh
Publication date
01-10-2011
Publisher
Springer US
Published in
Investigational New Drugs / Issue 5/2011
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-010-9460-0

Other articles of this Issue 5/2011

Investigational New Drugs 5/2011 Go to the issue

PHASE I STUDIES

Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies

PHASE II STUDIES

Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer

PRECLINICAL STUDIES

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice

PRECLINICAL STUDIES

In vitro pharmacological study of monomeric platinum(III) hematoporphyrin IX complexes

PHASE I STUDIES

A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies

SHORT REPORT

Kit inhibitor APcK110 extends survival in an AML xenograft mouse model
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits